Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc.RARE · Entity 4337 | See Remarks | April 16, 2026 | April 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Ultragenyx Pharmaceutical Inc.
Report date April 16, 2026 · Filed April 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 133,142 |
Reported balance
After 2026-04-16 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-04-16 · Grant · Acquired 23,116 · Balance 133,142 F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $24.52 · Expires 2036-04-16 | Direct | 79,936 |
Reported balance
After 2026-04-16 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-04-16 · Grant · Acquired 79,936 · Balance 79,936 F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. |
Filing footnotes · ownership attribution and instrument terms
F1: Award of Restricted Stock Units ("RSUs") under the Company's 2023 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date
F2: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions.
F3: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 01, 2018 Filed Jun 4, 2018 20:43 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 260 | $73.73 | $19,169.80 |
DisclosureSEC source: 0001209191-18-035151 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,330 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 514 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 30, 2018. Read SEC document |
| April 19, 2018 Filed Apr 19, 2018 20:49 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 1,431 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-025598 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,076 F1 · shares: Represents restricted stock units (RSUs) into which previously granted performance stock units were converted on April 19, 2018 upon certification of the applicable performance metric. Half of these RSUs will vest on the first anniversary of the certification date and the other half will vest on the second anniversary of the certification date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantStock Option (Right to Buy) · Derivative | 27,000 | $0.00 Strike: $48.43 | $0.00 |
DisclosureSEC source: 0001209191-18-016436 · doc4.xml · derivative · entry 3 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 27,000 Underlying: Common Stock · 27,000 shares Expires 2028-03-01 F5 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 276 | $48.43 | $13,366.68 |
DisclosureSEC source: 0001209191-18-016436 · doc4.xml · nonDerivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,645 F4 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of RSUs. Read SEC document |
| March 01, 2018 Filed Mar 5, 2018 21:21 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 5,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-016436 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,921 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. F3 · balance_after: Includes 38 shares acquired under the Company's 2014 Employee Stock Purchase Plan on October 31, 2017. Read SEC document |
| July 16, 2017 Filed Jul 17, 2017 20:24 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 705 | $64.36 | $45,373.80 |
DisclosureSEC source: 0001209191-17-045345 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,883 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. Read SEC document |
| June 01, 2017 Filed Jun 2, 2017 01:11 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | Tax withholdingCommon Stock | 282 | $56.61 | $15,964.02 |
DisclosureSEC source: 0001209191-17-036969 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,588 F1 · shares: Represents shares surrendered to the Issuer by the Reporting Person to pay required tax withholdings due to the vesting of Restricted Stock Units. F2 · balance_after: Includes 375 shares acquired under the Company's 2014 Employee Stock Purchase Plan on April 28, 2017. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantEmployee Stock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $88.80 | $0.00 |
DisclosureSEC source: 0001209191-17-016080 · doc4.xml · derivative · entry 2 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2027-03-01 F3 · derivative.exercise_date: On the first anniversary of the grant date of the option (the "Option Anniversary Date"), 1/4th of the shares initially subject to the option shall vest; thereafter, 1/48th of the shares initially subject to the option shall vest on each month as measured from the Option Anniversary Date. Read SEC document |
| March 01, 2017 Filed Mar 1, 2017 22:54 UTC | Ultragenyx Pharmaceutical Inc. RARE · Entity 4337 | GrantCommon Stock | 2,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-17-016080 · doc4.xml · nonDerivative · entry 1 Pinion John Richard · CIK 0001648096 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,495 F1 · shares: Award of Restricted Stock Units ("RSUs") under the Company's 2014 Incentive Plan. The RSUs shall vest with respect to 1/4th of the underlying shares on each anniversary of the grant date, such that the RSUs are fully vested on the fourth anniversary of the grant date. F2 · balance_after: Includes previously reported shares of common stock underlying RSUs granted to the Reporting Person, which are subject to certain vesting conditions. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.